RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

New anti-cancer therapies like RYBREVANT show promise in treating lung cancer with EGFR mutations, improving patient outcomes. The approval offers hope and improved quality of life, addressing significant treatment gaps.